Pasithea Financial Statements From 2010 to 2026

KTTAW Stock  USD 0.01  0.0003  2.86%   
Pasithea Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pasithea Therapeutics' valuation are provided below:
Revenue
486.6 K
Revenue Per Share
0.37
There are over one hundred six available trending fundamental ratios for Pasithea Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should check out Pasithea Therapeutics' recent fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable. Market Cap is likely to drop to about 3.8 M in 2026. Enterprise Value is likely to climb to about (3.8 M) in 2026
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 783.7 K, Other Operating Expenses of 10.4 M or Total Operating Expenses of 10.4 M, as well as many indicators such as Price To Sales Ratio of 2.2 K, Dividend Yield of 0.0 or PTB Ratio of 0.26. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Pasithea Stock
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Pasithea Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets31 M18.5 M11.3 M
Slightly volatile
Other Current Liabilities959.6 K1.3 M392.7 K
Slightly volatile
Total Current Liabilities1.3 M1.3 M516.4 K
Slightly volatile
Total Stockholder Equity29.1 M17 M10.6 M
Slightly volatile
Accounts Payable1.2 M1.3 M482.1 K
Slightly volatile
Cash5.9 M6.2 M7.3 M
Slightly volatile
Cash And Short Term Investments5.9 M6.2 M7.3 M
Slightly volatile
Common Stock Shares Outstanding1.2 M1.3 M868.7 K
Slightly volatile
Liabilities And Stockholders Equity31 M18.5 M11.3 M
Slightly volatile
Other Current Assets460.5 K512.4 K182.9 K
Slightly volatile
Other Stockholder Equity52.5 M74 M21.7 M
Slightly volatile
Total Liabilities1.9 M1.5 M707 K
Slightly volatile
Net Invested Capital29.1 M17 M10.6 M
Slightly volatile
Total Current Assets6.3 M6.6 M7.5 M
Slightly volatile
Capital Stock11912511.8 K
Slightly volatile
Net Working Capital5.3 M5.6 MM
Slightly volatile
Common Stock11912510.7 K
Slightly volatile
Property Plant And Equipment Gross140.8 K148.2 K131.8 K
Slightly volatile
Short and Long Term Debt Total69.8 K73.5 K403.7 K
Slightly volatile
Net Receivables34.6 K36.5 K240 K
Slightly volatile
Short Term Debt96.8 K73.5 K142.3 K
Slightly volatile
Intangible Assets6.4 M6.6 M8.2 M
Slightly volatile
Other Assets0.80.90.9824
Slightly volatile
Short Term Investments5.5 B6.2 B6.8 B
Slightly volatile

Pasithea Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization783.7 K746.4 K206.5 K
Slightly volatile
Other Operating Expenses10.4 M16.4 M4.4 M
Slightly volatile
Total Operating Expenses10.4 M16.4 M4.4 M
Slightly volatile
Interest Expense87.2191.8387
Slightly volatile
Selling General Administrative7.7 M8.1 M468.6 M
Pretty Stable
Cost Of Revenue783.7 K746.4 K178.8 K
Slightly volatile
Reconciled Depreciation783.7 K746.4 K161.5 K
Slightly volatile
Selling And Marketing Expenses9.5 B9.1 BB
Slightly volatile

Pasithea Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures2.182.39.6 K
Slightly volatile
End Period Cash Flow5.9 M6.2 M7.3 M
Slightly volatile
Stock Based Compensation734.9 K889.7 K557.7 K
Slightly volatile
Begin Period Cash Flow28.2 M18.8 MM
Slightly volatile
Depreciation783.7 K746.4 K167.6 K
Slightly volatile
Issuance Of Capital Stock31 M24.4 M43.5 M
Slightly volatile
Dividends Paid287.7 M323.7 M353.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.2 K2.4 K2.7 K
Slightly volatile
PTB Ratio0.260.27132
Slightly volatile
Book Value Per Share17.7212.148.4768
Slightly volatile
Average Payables408.9 K503.9 K176.1 K
Slightly volatile
Stock Based Compensation To Revenue25.0328.1630.7353
Slightly volatile
Capex To Depreciation0.00.012.2468
Slightly volatile
PB Ratio0.260.27132
Slightly volatile
Payables Turnover0.00280.00310.0034
Slightly volatile
Capex To Revenue1.141.281.402
Slightly volatile
Cash Per Share6.97.266.4447
Slightly volatile
Days Payables Outstanding84.9 K95.5 K104.3 K
Slightly volatile
Income Quality1.21.151.0135
Slightly volatile
Intangibles To Total Assets0.30.480.2645
Slightly volatile
Net Debt To EBITDA0.560.598.6208
Slightly volatile
Current Ratio7.197.5734.0039
Slightly volatile
Tangible Book Value Per Share6.196.516.1199
Slightly volatile
Shareholders Equity Per Share17.7212.148.4768
Slightly volatile
Debt To Equity0.00380.0040.0099
Slightly volatile
Capex Per Share0.00.00.0077
Slightly volatile
Graham Net Net5.625.925.8681
Slightly volatile
Revenue Per Share0.01050.01180.0129
Slightly volatile
Interest Debt Per Share0.05530.05830.0381
Slightly volatile
Debt To Assets0.00340.00360.0093
Slightly volatile
Enterprise Value Over EBITDA0.280.292.0749
Slightly volatile
Price Book Value Ratio0.260.27132
Slightly volatile
Days Of Payables Outstanding84.9 K95.5 K104.3 K
Slightly volatile
Ebt Per Ebit0.670.880.6008
Slightly volatile
Company Equity Multiplier0.860.981.0261
Pretty Stable
Total Debt To Capitalization0.00380.0040.0098
Slightly volatile
Debt Equity Ratio0.00380.0040.0099
Slightly volatile
Quick Ratio7.197.5734.0039
Slightly volatile
Net Income Per E B T1.221.181.171
Slightly volatile
Cash Ratio6.757.1133.4225
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0157
Slightly volatile
Price To Book Ratio0.260.27132
Slightly volatile
Fixed Asset Turnover0.60.670.7351
Slightly volatile
Enterprise Value Multiple0.280.292.0749
Slightly volatile
Debt Ratio0.00340.00360.0093
Slightly volatile
Price Sales Ratio2.2 K2.4 K2.7 K
Slightly volatile
Asset Turnover2.0E-43.0E-43.0E-4
Slightly volatile
Price Fair Value0.260.27132
Slightly volatile

Pasithea Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.8 MM35.9 M
Slightly volatile

Pasithea Fundamental Market Drivers

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics investors use historical fundamental indicators, such as Pasithea Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pasithea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.3 M-2.4 M
Cost Of Revenue746.4 K783.7 K
Stock Based Compensation To Revenue 28.16  25.03 
Capex To Revenue 1.28  1.14 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(269.33)(282.80)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.